Syneron Medical Ltd., a leading global aesthetic device company, has received CE Mark indication for its proprietary Sublative technology for the treatment of striae (stretch marks) and acne scars. The new treatment protocols are now available on all of the Syneron Sublative compatible systems, which include elos Plus, eTwo and eMatrix.

Stretch marks are one of the most common skin disorders, impacting 95 per cent of women during puberty or pregnancy, and can also occur in men and children. Historically difficult to treat, striae occur when the skin is stretched from rapid growth or weight gain, and causes damage to the connective tissue in the dermis.

Acne is a common condition experienced by up to 85 per cent of adolescents and young adults and 5 per cent of older adults. In some patients, the healing process results in permanent, disfiguring scars. Treatments ranged from chemical peels to ablative procedures with long recovery times and risky side effects.

With its new CE Mark clearance, Sublative has been shown to be an effective and safe way to reduce the appearance of stretch marks, acne scars and other skin irregularities in all skin types with minimal side effects, discomfort or downtime. The unique patented technology uses fractionated bi-polar radiofrequency directed to the skin in the form of a matrix. Due to its unique design, energy is deposited in the skin to initiate a healing response with minimal epidermal disruption. Patients benefit from a comfortable treatment with significant outcomes avoiding the potential complications of more aggressive treatments. After treatment with Sublative, the appearance of stretch marks and acne scars are greatly reduced.

"We have extensively studied the Sublative approach in the treatment of striae and found a noticeable and measurable improvement in the depth, width and colour of striae after very few treatments," states Maurice Adatto, Dermatologic Surgeon, Geneva, Switzerland, founder & Medical Director of SKINPULSE Derm & Laser Centres, Lecturer at Bern University Hospital.

The typical Sublative protocol consists of three to five treatments, spaced four to six weeks apart. Post treatment, patients can expect tone and texture improvements as a result of increased levels of collagen and elastin and new healthy skin cells, which are produced.

"Sublative resurfacing is my first line therapy for acne scarring, particularly for skin types IV - VI." said Amy Taub, MD from Chicago, Illinois, founder and Medical Director of Advanced Dermatology and skinfo, Clinical Assistant Professor at Northwestern University, Feinberg School of Medicine, and added: "I find it to be superior to non-ablative laser resurfacing with respect to downtime, discomfort and degree of complications such as acne and post inflammatory hyperpigmentation."

The addition of stretch mark treatment further expands Syneron's clinical utility and will allow physician customers to address a large segment of the aesthetic market. "We have received very positive physician and patient feedback on the Sublative technology since its introduction in 2009," states Amit Meridor, Syneron's CEO. "This patented fractional bi-polar radio frequency technology delivers excellent outcomes with little-to-no downtime and is a safe and more effective treatment alternative for all skin tones. We continue to create innovation solutions that further drive the aesthetic industry forward."

Syneron Medical Ltd. is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint.